See inside every stock. Pro
S&P 5007,723▲ 0.60%Nasdaq26,478▲ 1.18%Dow Jones52,378▲ 0.03%Nasdaq 10029,651▲ 1.29%VIX17.52▼ 4.73%US Dollar102.35▲ 0.39%Gold spot4,006▲ 0.30%WTI101.38▲ 1.48%
← PNV page
XStocksXray
Market X-Ray report · 27 October 2026

Polynovo Ltd (PNV)

Australian Securities Exchange · Australia · prices in AUD · close of 27 Oct 2026

Key indicators

Last closeAUD 0.870
52-week range0.810 – 1.420
Return, 1 month / 3 months−8.9% / +6.7%
Return, 1 year / 3 years−35.3% / −23.7%
TrendBelow its 200-day average
RSI (14)40
Volatility (1 year)50.8%
Worst drawdown (1 year)-40.7%
Average daily value traded1.63M AUD
Dividend yield–

Market X-Ray price-based

66/ 100 · High confidence · ahead of 72% of stocks on this exchange
Trend59
Momentum57
Stability (higher is calmer)71
Liquidity82
Income–

Five-year price chart navy: price · brown: 200-day average

0.701.231.772.302.832021-112023-022024-052025-082026-10

About the company

PolyNovo Ltd is a medical device company based in Melbourne, Australia, that develops and makes products for treating serious wounds and burns. Its main offering is a synthetic dermal template, built on the company's biodegradable polymer technology, which surgeons use to help regenerate skin in burns and complex wound reconstruction. Customers are hospitals, burns units and clinicians, and the company supplies these products in Australia and in overseas markets.

Polynovo Ltd trades under the code PNV on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

Polynovo Ltd (PNV) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.870 on 27 October 2026.

Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 512 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price fell 35.3% and over the last three months it rose 6.7%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
Polynovo Ltd (PNV)

The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange

Lens and metricValueScoreReading
Trend59 · FairMixed trend against its averages.
Above 200-day average-11.5%
From 52-week high-37.9%
Momentum57 · FairTypical recent returns for this exchange.
3-month return6.7%
6-month return-13.0%
12-month return, skipping the last month-29.0%
Stability (higher is calmer)71 · StrongCalmer than most: low volatility and shallow drawdowns.
Volatility, 1 year (lower is calmer)50.8%
Worst drawdown, 1 year (smaller is calmer)-40.7%
Liquidity82 · StrongTrades actively.
Average daily value traded1.63M AUD
Zero-volume days0.0%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

  • Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
  • Liquidity: Trades actively.

Weak spots

No lens is weak against its exchange.

Returns

1 week−3.9%
1 month−8.9%
3 months+6.7%
6 months−13.0%
1 year−35.3%
3 years−23.7%
5 years−54.1%

Signals

50-day / 200-day average0.964 / 0.984
Golden / death cross (60 days)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.033

Technical summary

DailyStrongly bearish1 bullish · 3 neutral · 12 bearish
WeeklyStrongly bearish0 bullish · 1 neutral · 11 bearish
MonthlyStrongly bearish0 bullish · 1 neutral · 7 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 28 Oct 2026